Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trials

Background It remains unclear how much various factors contribute to the placebo response. Aims To estimate the therapeutic impact of follow-up assessments on placebo response in antidepressant trials. Method Double-blind, placebo-controlled antidepressant trials that reported weekly changes in Hamilton Rating Scale for Depression (HRSD) scores over 6 weeks were selected. Included studies (n=41) were divided into those that conducted four, five or six follow-up assessments. Reductions in HRSD scores as a function of the different follow-up schedules were compared. Results An extra follow-up visit at week 3 was associated with a 0.86 further reduction in HRSD score; an extra visit at week 5 was associated with a 0.67 further reduction. These effects represented approximately 34–44% of the placebo response that occurred over these time frames. Two additional visits were associated with twice the reduction in HRSD score than one, suggesting that the therapeutic impact of assessment visits is cumulative and proportional. A comparable therapeutic effect was also found in participants receiving active medication. Conclusions Follow-up assessments in antidepressant treatment trials incur a significant therapeutic effect for participants on placebo, and this represents about 40% of the placebo response.

[1]  M. Thase.  Efficacy and Tolerability of Once-Daily Venlafaxine Extended Release (XR) in Outpatients With Major Depression , 1997 .

[2]  M. Thase.  How should efficacy be evaluated in randomized clinical trials of treatments for depression? , 1999, The Journal of clinical psychiatry.

[3]  B. Huitfeldt,et al.  A double-blind evaluation of zimelidine in comparison to placebo and amitmptyline in patients with major depressive disorder , 1983, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[4]  A. Kiev.  A double-blind, placebo-controlled study of paroxetine in depressed outpatients. , 1992, The Journal of clinical psychiatry.

[5]  Jacob Cohen.  Statistical Power Analysis for the Behavioral Sciences , 1969, The SAGE Encyclopedia of Research Design.

[6]  G. Tollefson,et al.  Response patterns of depressed outpatients with and without melancholia: a double-blind, placebo-controlled trial of fluoxetine versus placebo. , 1994, Journal of affective disorders.

[7]  A. Ontiveros,et al.  A double-blind comparison of nefazodone, imipramine, and placebo in major depression. , 1994, The Journal of clinical psychiatry.

[8]  L. Fabre,et al.  Comparison of alprazolam, imipramine, and placebo in the treatment of depression. , 1983, JAMA.

[9]  L. Fabre.  A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients. , 1992, The Journal of clinical psychiatry.

[10]  B. Diamond,et al.  A comparison of venlafaxine, trazodone, and placebo in major depression. , 1994, Journal of clinical psychopharmacology.

[11]  A. Ravindran,et al.  Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group. , 1999, The Journal of clinical psychiatry.

[12]  J. Mendels,et al.  Sertraline safety and efficacy in major depression: A double-blind fixed-dose comparison with placebo , 1995, Biological Psychiatry.

[13]  Ward T. Smith,et al.  Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder. , 1990, Psychopharmacology bulletin.

[14]  J. Cohn,et al.  A double‐blind, placebo‐controlled study comparing mianserin and amitriptyline in moderately depressed outpatients , 1994, International clinical psychopharmacology.

[15]  Clovoxamine in the treatment of depressed outpatients: a double-blind, parallel-group comparison against amitriptyline and placebo. , 1990, Comprehensive psychiatry.

[16]  Goldstein Bj,et al.  A double-blind placebo-controlled study of fluvoxamine and imipramine in depression. , 1985, The Journal of clinical psychiatry.

[17]  J. Endicott,et al.  The Naturalistic Course of Unipolar Major Depression in the Absence of Somatic Therapy , 2006, The Journal of nervous and mental disease.

[18]  A. Schatzberg.  Clinical efficacy of reboxetine in major depression. , 2000, The Journal of clinical psychiatry.

[19]  T. Baghai,et al.  Treatment of depressive outpatients with lorazepam, alprazolam, amytriptyline and placebo , 1995, Psychopharmacology.

[20]  D. Solomon,et al.  Integrating outcomes research into clinical practice. , 2002, Psychiatric services.

[21]  J. Mendels,et al.  Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study. , 1993, Psychopharmacology bulletin.

[22]  I. Kirsch,et al.  Listening to Prozac but Hearing Placebo: A Meta-Analysis of Antidepressant Medication , 1998 .

[23]  J. Cohn,et al.  A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder. , 1985, The Journal of clinical psychiatry.

[24]  G. Keitner,et al.  A reevaluation of the exclusion criteria used in antidepressant efficacy trials. , 2002, The American journal of psychiatry.

[25]  J. Feighner,et al.  A fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients. , 1990, The Journal of clinical psychiatry.

[26]  L. Cunningham.  Once-Daily Venlafaxine Extended Release (XR) and Venlafaxine Immediate Release (IR) in Outpatients with Major Depression , 1997, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[27]  Bremner Jd.  A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. , 1995 .

[28]  R. Allan.  The placebo effect. , 2006, Clinical medicine.

[29]  W. Brown,et al.  Are placebo controls necessary to test new antidepressants and anxiolytics? , 2002, The international journal of neuropsychopharmacology.

[30]  L. W. Buckalew,et al.  An Investigation of Drug Expectancy as a Function of Capsule Color and Size and Preparation Form , 1982, Journal of clinical psychopharmacology.

[31]  K. Jacobs,et al.  Classification of Placebo Drugs: Effect of Color , 1979, Perceptual and motor skills.

[32]  I. Kirsch.  How expectancies shape experience. , 1999 .

[33]  J. Feighner,et al.  Alprazolam, amitriptyline, doxepin, and placebo in the treatment of depression. , 1985, Archives of general psychiatry.

[34]  M. C. Khan,et al.  A randomised, double‐blind, placebo‐controlled, 5‐weeks' study of org 3770 (mirtazapine) in major depression , 1995 .

[35]  M. Versiani,et al.  A Double-blind Comparative Trial of Moclobemide v. Imipramine and Placebo in Major Depressive Episodes , 1989, British Journal of Psychiatry.

[36]  J. Feighner,et al.  A double‐blind, controlled evaluation of zimeldine, imipramine and placebo in patients with primary affective disorders , 1983, Acta psychiatrica Scandinavica. Supplementum.

[37]  R. Sysko,et al.  Placebo response in studies of major depression: variable, substantial, and growing. , 2002, JAMA.

[38]  J. Cohn,et al.  A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. , 1989, International clinical psychopharmacology.

[39]  J. Mendels,et al.  Comparative efficacy of alprazolam, imipramine, and placebo administered once a day in treating depressed patients. , 1986, The Journal of clinical psychiatry.

[40]  T M Itil,et al.  Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. , 1990, The Journal of clinical psychiatry.

[41]  M. Orne.  Demand Characteristics and the Concept of Quasi-Controls1 , 2009 .

[42]  J. Mendels,et al.  A double-blind, placebo-controlled trial of two dose ranges of nefazodone in the treatment of depressed outpatients. , 1995, The Journal of clinical psychiatry.

[43]  M. Zimmerman,et al.  Short-term spontaneous improvement rates in depressed outpatients. , 2000, The Journal of nervous and mental disease.

[44]  J. Feighner,et al.  Paroxetine in the treatment of depression: a comparison with imipramine and placebo , 1989, Acta psychiatrica Scandinavica. Supplementum.

[45]  K. Rickels,et al.  Adinazolam, Diazepam, Imipramine, and Placebo in Major Depressive Disorder: A Controlled Study* , 1991, Pharmacopsychiatry.

[46]  A. Feiger,et al.  A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. , 1999, Journal of affective disorders.

[47]  R. Bornstein,et al.  A meta-analysis of antidepressant outcome under "blinder" conditions. , 1992, Journal of consulting and clinical psychology.

[48]  J. Claghorn,et al.  Fluvoxamine maleate in the treatment of depression: a single-center, double-blind, placebo-controlled comparison with imipramine in outpatients. , 1996, Journal of clinical psychopharmacology.

[49]  ArifUllah Khan,et al.  The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group. , 1998, Journal of clinical psychopharmacology.

[50]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[51]  G. Dunbar,et al.  Paroxetine versus placebo: a double-blind comparison in depressed patients. , 1992, The Journal of clinical psychiatry.

[52]  S. Stahl.  Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline , 2000, Biological Psychiatry.

[53]  Mark Zimmerman,et al.  Is there a delay in the antidepressant effect? A meta-analysis. , 2005, The Journal of clinical psychiatry.

[54]  J. Amsterdam,et al.  A double-blind comparative trial of zimelidine, amitriptyline, and placebo in patients with mixed anxiety and depression. , 1986, Pharmacopsychiatry.

[55]  J. Amsterdam,et al.  The efficacy and safety of paroxetine compared with placebo in outpatients with major depression. , 1992, The Journal of clinical psychiatry.

[56]  A. Schatzberg,et al.  Serotonin activity in psychotic (delusional) major depression. , 1992, The Journal of clinical psychiatry.

[57]  E. Robins,et al.  Research diagnostic criteria: rationale and reliability. , 1978, Archives of general psychiatry.

[58]  W. Byerley,et al.  Fluoxetine, a Selective Serotonin Uptake Inhibitor, for the Treatment of Outpatients with Major Depression , 1988, Journal of clinical psychopharmacology.

[59]  R. Rosenthal,et al.  Artifact in behavioral research , 1969 .

[60]  J. Claghorn,et al.  A double-blind placebo-controlled study of Org 3770 in depressed outpatients. , 1995, Journal of affective disorders.

[61]  L. Fabre,et al.  A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. , 1998, The Journal of clinical psychiatry.

[62]  L. M. Omer,et al.  Cianopramine and amitriptyline in the treatment of depressed patients — a placebo-controlled study , 2004, Psychopharmacology.

[63]  Irving Kirsch,et al.  Response expectancy as a determinant of experience and behavior. , 1985 .

[64]  W. Smith,et al.  A placebo-controlled trial of paroxetine in the treatment of major depression. , 1992, The Journal of clinical psychiatry.

[65]  R. Fuller.  Basic advances in serotonin pharmacology. , 1992, The Journal of clinical psychiatry.

[66]  R. Shrivastava,et al.  A double-blind comparison of paroxetine, imipramine, and placebo in major depression. , 1992, The Journal of clinical psychiatry.